



**HAL**  
open science

## **Lifestyle and incident dementia: A COSMIC individual participant datameta-analysis.**

Stephanie van Asbroeck, Sebastian Köhler, Martin P J van Boxtel, Darren M Lipnicki, John D Crawford, Erico Castro-Costa, Maria Fernanda Lima-Costa, Sergio Luis Blay, Xiao Shifu, Tao Wang, et al.

### ► **To cite this version:**

Stephanie van Asbroeck, Sebastian Köhler, Martin P J van Boxtel, Darren M Lipnicki, John D Crawford, et al. Lifestyle and incident dementia: A COSMIC individual participant datameta-analysis.. Alzheimer's & Dementia: the Journal of the Alzheimer's Association, 2024, 10.1002/alz.13846 . ird-04562477

**HAL Id: ird-04562477**

**<https://ird.hal.science/ird-04562477>**

Submitted on 29 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## RESEARCH ARTICLE

# Lifestyle and incident dementia: A COSMIC individual participant data meta-analysis

Stephanie Van Asbroeck<sup>1</sup>  | Sebastian Köhler<sup>1</sup> | Martin P. J. van Boxtel<sup>1</sup> |  
 Darren M. Lipnicki<sup>2</sup> | John D. Crawford<sup>2</sup> | Erico Castro-Costa<sup>3</sup> |  
 Maria Fernanda Lima-Costa<sup>3</sup> | Sergio Luis Blay<sup>4</sup> | Xiao Shifu<sup>5</sup> | Tao Wang<sup>5,6,7</sup> |  
 Ling Yue<sup>5</sup> | Richard B. Lipton<sup>8,9,10</sup> | Mindy J. Katz<sup>8</sup> | Carol A. Derby<sup>8,9</sup> |  
 Maëlen Guerchet<sup>11</sup> | Pierre-Marie Preux<sup>11</sup> | Pascal Mbelesso<sup>12</sup> | Joanna Norton<sup>13</sup> |  
 Karen Ritchie<sup>13,14</sup> | Ingmar Skoog<sup>15,16,17</sup> | Jenna Najjar<sup>15,16,17,18</sup> |  
 Therese Rydberg Sterner<sup>15,16,19</sup> | Nikolaos Scarmeas<sup>20,21</sup> | Mary Yannakoulia<sup>22</sup> |  
 Themis Dardiotis<sup>23</sup> | Elena Rolandi<sup>24,25</sup> | Annalisa Davin<sup>24</sup> | Michele Rossi<sup>24</sup> |  
 Oye Gureje<sup>26</sup> | Akin Ojagbemi<sup>27</sup> | Toyin Bello<sup>27</sup> | Ki Woong Kim<sup>28,29,30</sup> |  
 Ji Won Han<sup>28,29</sup> | Dae Jong Oh<sup>31</sup> | Stella Trompet<sup>32</sup> | Jacobijn Gussekloo<sup>32,33</sup> |  
 Steffi G. Riedel-Heller<sup>34</sup> | Susanne Röhr<sup>34,35,36</sup> | Alexander Pabst<sup>34</sup> | Suzana Shahar<sup>37</sup> |  
 Nurul Fatin Malek Rivani<sup>37</sup> | Devinder Kaur Ajit Singh<sup>37</sup> | Erin Jacobsen<sup>38</sup> |  
 Mary Ganguli<sup>38,39</sup> | Tiffany Hughes<sup>40</sup> | Mary Haan<sup>41</sup> | Allison E. Aiello<sup>42</sup> |  
 Ding Ding<sup>43</sup> | Qianhua Zhao<sup>43</sup> | Zhenxu Xiao<sup>43</sup> | Kenji Narazaki<sup>44</sup> | Tao Chen<sup>45</sup> |  
 Sanmei Chen<sup>46</sup> | Tze Pin Ng<sup>47</sup> | Xinyi Gwee<sup>47</sup> | Qi Gao<sup>47</sup> | Henry Brodaty<sup>2</sup> |  
 Julian Trollor<sup>2,48</sup> | Nicole Kochan<sup>2</sup> | Antonio Lobo<sup>49,50,51</sup> | Javier Santabárbara<sup>50,51,52</sup> |  
 Patricia Gracia-Garcia<sup>49,50,51</sup> | Perminder S. Sachdev<sup>2,53</sup> | Kay Deckers<sup>1</sup> | for Cohort  
 Studies of Memory in an International Consortium (COSMIC)

**Funding information**

National Institute on Aging, Grant/Award Number: AG03949; National Institutes of Health, Grant/Award Numbers: RF1AG057531, AG03949, R37AG02365; Maastricht University Medical Center; Netherlands Programme for Research on Aging (NESTOR); Netherlands Organisation for Health Research and Development (ZonMw), Grant/Award Number: 733050511; Wellcome Trust; Associazione Alzheimer Milano; Fondo de Investigación Sanitaria; Spanish Ministry of Economy and Competitiveness, Madrid, Spain, Grant/Award Numbers: 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, 12/02254, 16/00896, PI/19/01874, G03/128; Fondo Europeo de Desarrollo Regional (FEDER) of the European Union "Una manera de hacer Europa", Grant/Award Number: PI16/00896; Gobierno de Aragón, Grant/Award Numbers: B15\_17R, B15\_23R; Alzheimer's Association, Grant/Award Numbers: IIRG-09-133014, 189 10276/8/9/2011; National Strategic Reference Framework (NSRF) - EU Program Excellence Grant (ARISTEIA); European Social Fund; Ministry for Health and Social Solidarity (Greece); China Ministry of Science and Technology, Grant/Award Number: 2009BAI77B03; Clinical Research Center, Shanghai Mental Health Center, Grant/Award Number: CRC2017ZD02; Shanghai Brain Health Foundation; Agency for Science Technology and Research (A\*STAR) Biomedical Research Council, Grant/Award Number: BMRC/08/1/21/19/567; National Medical Research Council, Grant/Award Numbers: NMRC/1108/2007, NMRC/CIRG/1409/2014; French National Research Agency, Grant/Award Number: ANR-09-MNPS-009-01; AXA Research Fund, Grant/Award Number: 2012-Project Public Health Institute [Inserm]-PREUX Pierre-Marie; Limoges University Hospital Appel à Projet des Equipes Émergentes et Labellisées scheme (APREL); Leonard and Sylvia Marx Foundation; Czup Foundation; NIH/NIA, Grant/Award Numbers: AG03949, R37AG02365; Long-term Research Grant Scheme (LGRS) Ministry of Higher Education, Malaysia, Grant/Award Numbers: LRGS/1/2019/UM-UKM/1/4, LRGS/BU/2012/UKM-UKM/K/01; Universiti Kebangsaan Malaysia Grand Challenge, Grant/Award Numbers: DCP-2017-002/1, DCP-2017-002/2; Interdisciplinary Centre for Clinical Research University of Leipzig (Interdisziplinäres Zentrum für Klinische Forschung/IZKF), Grant/Award Number: 01KS9504; JSPS KAKENHI, Grant/Award Numbers: JP17K09146, 20H04030; Alzheimer's fonden, Grant/Award Number: AF-967865; ALF-agreement, Grant/Award Number: 72660; Stiftelsen Hjalmar Svenssons forskningsfond, Grant/Award Numbers: HJSV2022059, HJSV2023023; Fondazione CARIPO, FrailBioTrack Project, Grant/Award Number: 2017-0557; AgeCap-Center for Aging and Health; Riksbankens Jubileumsfond; FORTE; Swedish Brain Power; Swedish Research Council; Swedish Research Council for Health, Working Life and Welfare; Epilife; The Alzheimer's Association Zenith Award; The Alzheimer's Association Stephanie B Overstreet Scholars; The Bank of Sweden Tercentenary Foundation; Stiftelsen Söderström-Königska Sjukhemmet; Stiftelsen för Gamla Tjänarinnor; Handlanden Hjalmar Svenssons Forskningsfond; Stiftelsen Professor Bror Gadelius' Minnesfond; Instituto de Salud Carlos III; Greek National Resources

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

**Correspondence**

Kay Deckers, Alzheimer Centrum Limburg,  
Department of Psychiatry and  
Neuropsychology, Mental Health and  
Neuroscience (MHeNs) Research Institute,  
Maastricht University, P.O. Box 616 (UNS40  
BOX34), 6200 MD Maastricht, the  
Netherlands.  
Email: [kay.deckers@maastrichtuniversity.nl](mailto:kay.deckers@maastrichtuniversity.nl)

**Abstract**

**INTRODUCTION:** The Lifestyle for BRAin Health (LIBRA) index yields a dementia risk score based on modifiable lifestyle factors and is validated in Western samples. We investigated whether the association between LIBRA scores and incident dementia is moderated by geographical location or sociodemographic characteristics.

**METHODS:** We combined data from 21 prospective cohorts across six continents ( $N = 31,680$ ) and conducted cohort-specific Cox proportional hazard regression analyses in a two-step individual participant data meta-analysis.

**RESULTS:** A one-standard-deviation increase in LIBRA score was associated with a 21% higher risk for dementia. The association was stronger for Asian cohorts compared to European cohorts, and for individuals aged  $\leq 75$  years (vs older), though only within the first 5 years of follow-up. No interactions with sex, education, or socioeconomic position were observed.

**DISCUSSION:** Modifiable risk and protective factors appear relevant for dementia risk reduction across diverse geographical and sociodemographic groups.

**KEYWORDS**

age, dementia, dementia risk reduction, education, effect modification, ethnicity, individual participant data meta-analysis, interaction, lifestyle, primary prevention, region, risk factor, risk personalization, sex, socioeconomic

**Highlights**

- A two-step individual participant data meta-analysis was conducted.
- This was done at a global scale using data from 21 ethno-regionally diverse cohorts.
- The association between a modifiable dementia risk score and dementia was examined.
- The association was modified by geographical region and age at baseline.
- Yet, modifiable dementia risk and protective factors appear relevant in all investigated groups and regions.

**1 | BACKGROUND**

Due to the aging of the population and lack of curative treatments, dementia prevalence is expected to increase from 55 million cases worldwide in 2019 to 139 million cases by 2050, further heightening the already large burden of disease associated with this group of conditions.<sup>1</sup> However, evidence supporting the potential for dementia risk reduction by targeting modifiable risk and protective factors has been steadily accumulating.<sup>2,3</sup> About 40% of all dementia cases worldwide have been estimated to be potentially attributable to 12 modifiable risk and protective factors.<sup>4</sup> Many of these factors also overlap with the World Health Organization's recommendations to reduce dementia risk.<sup>5</sup>

However, it is currently unclear whether dementia risk should be further personalized, or at least stratified, based on sociodemographic or other characteristics. Exploring risk stratification may lead to more accurate and inclusive risk estimates.<sup>6</sup> For instance, the risk conferred by certain modifiable risk factors has been demonstrated to differ

depending on the age of exposure. This has been the case for obesity, hypertension, and dyslipidemia which have been shown to be more strongly associated with dementia when their exposure occurs in mid-life rather than in late life.<sup>2,7,8</sup> However, little is known about whether other sociodemographic variables, such as sex, race and ethnicity, educational level, and socioeconomic position (SEP), or geographical location modify the association between modifiable risk and protective factors and incident dementia. Yet, this information may indicate where most preventive potential lies, which is important information for policy makers and individuals themselves.

To date, some studies from high income, Western countries have observed no effect modification by education or SEP,<sup>9-11</sup> and studies looking at sex have shown varying results.<sup>12-15</sup> There are reports of continent-level differences in the association between alcohol consumption and dementia risk<sup>13</sup> and a stronger association between diabetes and cognitive decline in samples from Asian countries compared to samples from Europe, North America, and Australia with predominantly White participants.<sup>16</sup> Yet, in general the research on

potential (ethno-) regional differences in associations between modifiable risk factors and future cognitive status is scarce. Therefore, risk personalization for all known modifiable risk and protective factors needs to be further investigated. In the case of dementia, composite modifiable risk scores such as the Lifestyle for BRAin Health (LIBRA) index<sup>8,17</sup> or the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI<sup>18</sup>) are also relevant to consider due to the syndrome's multifactor etiology.<sup>19,20</sup> These composite risk scores combine the presence or absence of multiple factors into one numeric value that expresses dementia risk. They are especially valuable as they can aid in the identification of individuals at high risk and may facilitate the implementation of dementia risk reduction guidelines into practice.<sup>19</sup>

The LIBRA index includes only modifiable risk (ie, physical inactivity, current smoking, obesity, hypertension, dyslipidemia, diabetes, depression, coronary heart disease [CHD], and chronic kidney disease [CKD]) and protective (ie, low-to-moderate alcohol consumption, healthy diet, high cognitive activity) factors.<sup>8,17</sup> The score has been well validated for predicting incident dementia in cohorts located in Western, high-income countries.<sup>9,16–21</sup> However, its predictive validity has not been explored in populations living in other regions. The current study aims to assess whether the association between the LIBRA index and incident dementia is moderated by sociodemographic characteristics, including age, sex, education, and SEP, or by geographical location.

## 2 | METHODS

### 2.1 | Contributing studies

In this individual-participant data meta-analysis, data from 21 cohorts, drawn from 17 countries across six continents, were used. All cohorts are part of the Cohort Studies of Memory in an International Consortium (COSMIC) collaboration.<sup>21</sup> Details of the individual studies can be found in Table 1.

Exclusion criteria were the following: prevalent dementia, missing information on dementia status or length of follow-up, no available follow-up assessment, or insufficient data on modifiable risk and protective factors (ie, fewer than seven out of the 12 LIBRA factors, Figure 1).

This study was approved by the University of New South Wales Human Research Ethics committee (HC17292 and HC220222). All individual cohorts had previously received local ethical approval (see Material S1).

### 2.2 | Sociodemographic characteristics and geographical location

Age and sex data were available in all cohorts. Educational level was operationalized as total years of formal education. If unavailable, categories of educational attainment were converted to total years of formal education after consultation with local study coordinators. For a

### Research in context

- 1. Systematic review:** The authors reviewed the current state-of-evidence regarding modifiable risk factors for dementia using traditional sources (eg, PubMed). Risk personalization or stratification beyond age has rarely been explored whereas doing so could identify groups with the most preventive potential and is necessary for inclusive and accurate risk estimation.
- 2. Interpretation:** Our results suggest that modifiable factors, compiled in a modifiable dementia risk score, are associated with dementia risk regardless of sex, age, educational level, socioeconomic position, or broad geographical region. However, this association was even stronger in younger individuals ( $\leq 75$  years) and in Asian cohorts compared to European cohorts.
- 3. Future directions:** These findings need to be replicated. More data and research are needed particularly regarding geographical region. Cohort studies conducted in multiple regions would be ideal. Future work should also examine potential interactions between individual modifiable risk factors (rather than an index) and sociodemographic or environmental characteristics.

stratified analysis, years of formal education were categorized into low ( $< 6$  years of formal education), intermediate (6 to 11 years of formal education) and high ( $\geq 12$  years of formal education). SEP was categorized as low, middle, or high within each cohort, based on several alternative measures, predominantly income and occupation, to maximize harmonization potential. See Material S2 for the sociodemographic characteristics' harmonization protocols. Geographical location was defined as the continent where the cohort was sampled. Within nearly every cohort the sample was predominantly homogeneous in terms of broad racial and ethnic group. Race and ethnicity, and geographical location, overlapped almost entirely: non-Hispanic White in Europe and Australia, Asian in Asia, and non-Hispanic Black in Africa. The cohorts in North America included one predominantly non-Hispanic White (MYHAT), one fully Hispanic (SALSA, no further specification on White or Black but mostly of Mexican origin), and one mixed (EAS: non-Hispanic White, Hispanic White, non-Hispanic Black, and Hispanic Black). The only cohort in South America (Bambui) was from Brazil, a country known to have a very complex and hard to define racial and ethnic makeup.<sup>43</sup>

### 2.3 | Modifiable risk and protective factors: LIBRA score

Modifiable risk factors were summarized in the LIBRA score, a weighted compound score that combines the presence or absence of

**TABLE 1** Contributing studies, in alphabetical order.

Study	Abbreviation	Location (continent)	Year started	n included (% of total sample)
Bambui cohort study of ageing <sup>22</sup>	Bambui	Bambui, Brazil (South America)	1997	1336 (83.2)
China longitudinal aging study <sup>23</sup>	CLAS	China (Asia)	2011	1872 (57.7)
Einstein aging study <sup>24</sup>	EAS	New York City, NY, United States (North America)	1993	1022 (44.7)
Epidemiology of dementia in central Africa <sup>25</sup>	EPIDEMCA	Gamboma and Brazzaville, Republic of Congo (Africa)	2011	689 (70.0)
Enquête de Santé Psychologique—Risques, Incidence et Traitement <sup>26</sup>	ESPRIT	Montpellier, France (Europe)	1999	1983 (87.8)
The Gothenburg H70 Birth cohort study <sup>27</sup>	the H70 study	Gothenburg, Sweden (Europe)	1971	902 (73.9)
Hellenic longitudinal investigation of aging and diet <sup>28</sup>	HELIAD	Larissa and Marousi, Greece (Europe)	2010	1001 (48.1)
Invecchiamento Cerebrale in Abbiategrosso <sup>29</sup>	InveCe.Ab	Abbiategrosso, Italy (Europe)	2010	1107 (83.8)
Ibadan study of ageing <sup>30</sup>	ISA	Ibadan, Nigeria (Africa)	2003	1244 (57.9)
Korean longitudinal study on cognitive aging and dementia <sup>31</sup>	KLOSCAD	South Korea (Asia)	2009	5109 (75.0)
Leiden 85-plus study <sup>32</sup>	Leiden 85+	Leiden, the Netherlands (Europe)	1997	485 (81.0)
Leipzig longitudinal study of the aged <sup>33</sup>	LEILA 75+	Leipzig, Germany (Europe)	1997	891 (70.4)
The longitudinal study on neuroprotective model for healthy longevity <sup>34</sup>	LRGS TUA	Malaysia (Asia)	2012	1006 (43.2)
Maastricht aging study <sup>35</sup>	MAAS	South Limburg, the Netherlands (Europe)	1993	1643 (61.8)
Monongahela-Youghiohgheny healthy aging team <sup>36</sup>	MYHAT	Allegheny County, PA, United States (North America)	2006	1653 (86.1)
Sacramento area Latino study on aging <sup>37</sup>	SALSA	Sacramento area, CA, United States (North America)	1998	1471 (82.2)
Shanghai aging study <sup>38</sup>	SAS	Shanghai, China (Asia)	2010	1657 (43.2)
Sasaguri Genkimon Study <sup>39</sup>	SGS	Sasaguri, Japan (Asia)	2011	1050 (39.9)
Singapore longitudinal ageing study II <sup>40</sup>	SLAS II	Singapore (Asia)	2003	1433 (43.8)
Sydney memory and ageing study <sup>41</sup>	MAS	Sydney, Australia (Oceania)	2005	900 (86.8)
Zaragoza dementia depression project <sup>42</sup>	ZARADEMP	Zaragoza, Spain (Europe)	1994	3226 (67.2)

12 modifiable risk and protective factors for dementia.<sup>8,17</sup> Each risk and protective factor has an assigned weight based on the factor's relative risk for dementia from published meta-analyses.<sup>8,17</sup> Based on the presence or absence of the factor, these weights (see [Material S2](#)) are summed to yield the total LIBRA score, ranging from -5.9 to +12.7. Higher scores indicate a less favorable combination of risk factors and a higher risk for dementia. The LIBRA index has been extensively validated to predict brain damage (ie, white matter hyperintensities volume on neuroimaging), cognitive decline, incident cognitive impairment, and dementia risk in various population-based studies.<sup>10,17,44-48</sup>

Here, the presence or absence of each factor was determined for every individual, based on the harmonization protocols described in [Material S2](#). If possible, missing information at baseline was augmented with information at follow-up assessments. At least seven of the 12 factors had to be available for an individual to be included in the analyses (Figure 1). When not all factors were known, the LIBRA score was


calculated with the available factors and rescaled to the full theoretical range (ie, when all 12 factors would be present) using the standard min-max normalization formula given as follows in Equation (1),

$$LIBRA_{scaled} = \frac{LIBRA_{crude} - a}{b - a} \times (12.7 - (-5.9)) + (-5.9) \quad (1)$$

where *a* and *b* are the lower and upper limits, respectively, of the LIBRA score with the available factors.

## 2.4 | Dementia incidence

Determination of incident dementia varied across studies. Twelve studies used Diagnostic and Statistical Manual of Mental Disorders (DSM) III or IV criteria.<sup>49,50</sup> A few cohorts employed other assessment methods, such as the Clinical Dementia Rating (CDR<sup>51</sup>), the Mini-Mental State Examination (MMSE<sup>52</sup>), or a self-reported



**FIGURE 1** Flow chart of sample selection. LIBRA, Lifestyle for BRAin Health (index).

diagnosis. It was not possible to distinguish between different etiologies, as brain imaging, biomarkers, or autopsy data were not available. The harmonization protocol can be found in [Material S2](#).

## 2.5 | Statistical analyses

A two-step individual participant data meta-analysis approach was used. Potential associations between sociodemographic characteristics and LIBRA score at baseline were examined by calculating the cohort-specific differences in mean LIBRA score between the sociodemographic groups. Next, these mean differences were pooled using random-effects meta-analysis resulting in pooled mean differences and their 95% confidence intervals (CIs).

The LIBRA score was also compared between geographical locations. Here, mean LIBRA scores were pooled per continent and compared using a Cochran's Q test. The  $I^2$  statistic was used to assess heterogeneity between studies. Meta-regression was used to confirm the results from the Cochran's Q test and estimate the mean difference in LIBRA score between continents.

Cox proportional hazard regression analysis was used to assess the association between the LIBRA score and dementia incidence in each cohort separately, resulting in hazard ratios (HRs) and their 95% CIs.

This was done for the continuous LIBRA score as well as for cohort-specific LIBRA score tertiles. In all analyses, age was used as the time scale and dementia was treated as the failure event. Survival time was defined as the age at study entry until the age at the date of dementia diagnosis (if reported, otherwise calculated as the mid-point between waves) or study exit (ie, date of last interview or date of death, whichever came first). Three different models were run, controlling for the following variables: Model 1 = crude model (age only); Model 2 = Model 1 + sex and years of formal education (main model); and Model 3 = Model 2 + SEP. Model 3 was defined as a separate model because data on SEP were not available in a significant portion of the sample. Also because of this, Model 2 is regarded as the main model. As dementia's pathology develops over many years before diagnosis, additional analyses were carried out in which survival time within each cohort was split up into an early follow-up ( $\leq 5$  years after baseline) and a late follow-up ( $> 5$  years after baseline). This allows us to distinguish between incident cases that were likely already in the preclinical stage at baseline, and cases that developed later. Each Cox regression analysis had to have at least five events (ie, incident dementia cases) per variable in the model (ie, LIBRA score + control variables).<sup>53</sup> The proportional hazard assumption was assessed by testing of Schoenfeld residuals.<sup>54</sup> One cohort (Gothenburg H70 Birth cohort study [the H70 study]) showed non-proportional hazards. As there is no straightforward remedy for this, without compromising the ability to compare and pool the results of analyses over all cohorts, this cohort was still included in the analyses. However, an additional sensitivity analysis without the H70 study was carried out. To examine the moderating effect of the sociodemographic variables described earlier, Cox regression analyses, stratified by these variables, were executed. Baseline age was stratified into individuals  $\leq 75$  versus older, as LIBRA was initially designed for capturing modifiable dementia risk in people aged 40 to 75 years and has been shown to perform less well after the age of 75.<sup>7,44</sup> All cohort-specific HRs were pooled using random effects meta-analysis. Cochran's Q statistic for subgroup differences was used to test the potential moderating effect of the selected sociodemographic variables and geographical location on the association between LIBRA and dementia incidence with an alpha level of 0.10.<sup>55</sup> The  $I^2$  statistic was used to assess heterogeneity between studies. Additionally, meta-regression was used to examine potential sources of heterogeneity (including proportion of females, median age, median follow-up time, number of available LIBRA factors in a cohort, continent, and gross-domestic product per capita of the country where the cohort was based<sup>56</sup>). All tests were carried out two-sided with an alpha level of 0.05 unless indicated otherwise. All analyses were conducted with Stata 17.0 (StataCorp, College Station, Texas, United States).

## 3 | RESULTS

In total, 31,680 eligible individuals from 21 cohorts across six continents were included (mean age range at baseline: 52 to 85 [SD range across cohorts: 0 to 16], 58% female, Figure 1). A total of 2330 incident dementia cases were recorded during an overall median of 5.0 years of follow-up (range: 1.0 to 2.4 years). Of these, 1671



**TABLE 2** Cohort-specific population characteristics.

Cohort	Age, median (IQR)	Female sex, n (%)	Years of formal education, median (IQR)	LIBRA index, median (IQR)	Median follow-up, years	Dementia incidence, n (%)
Bambui	67 (10)	829 (62)	3 (4)	2.9 (3.5)	11.0	173 (12)
CLAS	71 (13)	1008 (54)	9 (8)	−0.1 (3.9)	1.0	162 (9)
EAS	77 (8)	635 (62)	14 (4)	1.3 (4.2)	3.8	154 (11)
EPIDEMCA	72 (10)	407 (59)	0 (3)	1.6 (4.4)	1.9	36 (5)
ESPRIT	72 (7)	1168 (59)	11 (3)	2.0 (3.4)	11.5	210 (11)
the H70 study	70 (8)	672 (75)	8 (4)	3.2 (3.5)	11.7	146 (16)
HELIAD	72 (7)	597 (60)	6 (7)	3.0 (3.3)	3.0	56 (6)
InveCe.Ab	72 (2)	598 (54)	5 (3)	1.0 (3.7)	8.1	111 (10)
ISA	72 (11)	639 (51)	0 (5)	−2.0 (4.3)	5.5	136 (11)
KLOSCAD	69 (10)	2898 (57)	9 (6)	−2.2 (3.4)	5.5	252 (5)
Leiden 85+	85 (0)	315 (65)	6 (3)	1.9 (3.7)	5.0	64 (13)
LEILA 75+	80 (7)	653 (73)	12 (1)	3.8 (4.5)	4.1	214 (22)
LRGS TUA	67 (8)	525 (52)	6 (7)	1.5 (3.8)	5.0	48 (5)
MAAS	51 (26)	796 (48)	11 (4)	−0.7 (3.5)	12.4	62 (4)
MYHAT	78 (12)	1028 (62)	12 (2)	0.9 (4.4)	6.1	105 (6)
SALSA	69 (10)	856 (58)	7 (9)	2.0 (4.5)	7.7	103 (7)
SAS	71 (12)	900 (54)	12 (6)	−0.3 (4.0)	5.2	167 (10)
SGS	72 (9)	583 (56)	12 (3)	−2.9 (2.9)	2.0	5 (0.5)
SLAS II	65 (10)	929 (65)	6 (7)	0.6 (3.0)	4.2	11 (1)
MAS	78 (7)	488 (54)	11 (5)	2.4 (3.8)	5.8	106 (12)
ZARADEMP	70 (13)	1784 (55)	8 (3)	−3.1 (2.6)	4.5	138 (4)
<b>Total</b>	<b>71 (11)</b>	<b>18,308 (58)</b>	<b>9 (7)</b>	<b>0.2 (4.8)</b>	<b>5.0</b>	<b>2330 (7)</b>

Note: LIBRA theoretical range: −5.9 to +12.7, missing data: CLAS: sex:  $n = 2$ , years of formal education:  $n = 6$ . Expansions of cohort name abbreviations are presented in Table 1.

Abbreviations: IQR, interquartile range; LIBRA, Lifestyle for BRAin Health.

dementia cases were diagnosed  $\leq 5$  years after baseline, and 659 cases were diagnosed later ( $>5$  years after baseline). Detailed, cohort-specific population characteristics can be found in Table 2. The cohort-specific distribution of individual LIBRA factors can be consulted in Material S2. Included individuals were compared with those who were excluded. Across the cohorts, included individuals were typically younger and had more years of formal education. They also tended to be less likely to have conditions such as hypertension, diabetes, or depression, but were more likely to have dyslipidemia. A full comparison can be found in Material S3.


### 3.1 | LIBRA index across sociodemographic strata and geographical location

Potential baseline differences in mean LIBRA scores between sociodemographic strata and geographical location were assessed. Mean (95% CI) LIBRA scores were 0.5 (0.27 to 0.72) points higher (worse) in older individuals ( $\leq 75$  vs  $>75$  years old). LIBRA scores were also higher in individuals with fewer years of formal education or a lower SEP. For education, compared to 6 to 11 years, those with  $<6$  years were 0.52

points higher and those with  $\geq 12$  years were 0.58 points lower (all  $p < 0.05$ ). For SEP, compared to those with an intermediate SEP, those with a lower SEP were 0.39 points higher and those with a high SEP were 0.39 points lower (all  $p < 0.05$ ). Mean LIBRA scores did not differ significantly between males and females. Forest plots of individual study data can be found in Material S4. LIBRA scores were also compared based on the geographical location of the cohort (Figure 2). This showed large heterogeneity both within and between continental regions. LIBRA scores were on average 2.1 (95% CI = −3.8 to −0.3) points lower in Asian cohorts compared to European cohorts ( $p = 0.020$ ).


### 3.2 | LIBRA and dementia incidence

On a continuous scale, a one-point increase in the LIBRA score was significantly associated with a higher risk for dementia (HR = 1.06, 95% CI = 1.04 to 1.08) in main Model 2 (Figure 3 and Table 3). Per one SD increase in LIBRA (over all participants in all cohorts combined: SD = 3.26), this translates to HR = 1.21 (95% CI = 1.14 to 1.29). Heterogeneity was limited ( $I^2 = 31.1\%$ ). The hazard for dementia was 33%



**FIGURE 2** Mean LIBRA score by cohort and continent. Expansions of cohort name abbreviations are presented in Table 1. CI, confidence interval; LIBRA, Lifestyle for BRAin Health.





**FIGURE 3** Hazard ratio for incident dementia per one-point increase in LIBRA score. Model 2 (main model), controlled for age (time scale), sex, and years of formal education. Expansions of cohort name abbreviations are presented in Table 1. CI, confidence interval; HR, hazard ratio; LIBRA, Lifestyle for BRAin Health.

higher in the highest LIBRA tertile compared to the lowest (Model 2, Table 3).

When examining early and late follow-up, the LIBRA index was associated with dementia incidence, both in individuals who developed dementia within 5 years (HR = 1.06, 95% CI = 1.03 to 1.09, Model 2) and in individuals who developed dementia after more than 5 years (also HR = 1.06, 95% CI = 1.03 to 1.09, Model 2).

### 3.3 | Potential moderating effect of sociodemographic characteristics and geographical location on the association between LIBRA and incident dementia

Potential interactions between LIBRA, sociodemographic characteristics and geographical location were explored using meta-analysis and

Cochran's Q statistic for subgroup differences (Figure 4 and Material S5), as well as meta-regression (Material S6).


The association between LIBRA and dementia incidence did not differ between males and females, regardless of timing during the follow-up. Further, years of formal education and SEP did not interact with LIBRA. When comparing the association between LIBRA and incident dementia among younger ( $\leq 75$  years old) and older ( $> 75$  years old) individuals across the entire follow-up time, evidence for an interaction was observed. With higher LIBRA scores, the risk increase was larger in younger individuals (1.08, 95% CI = 1.05 to 1.11) than in older individuals (1.04, 95% CI = 1.02 to 1.07,  $p_{\text{interaction}} = 0.035$ ). Meta-regression confirmed that median age at baseline was indeed a significant moderator. However, this interaction was only apparent in the early follow-up period (Cochran's Q test, Model 2 younger: 1.12, 95% CI = 1.09 to 1.15, vs older: 1.03, 95% CI = 1.01 to 1.06,  $p_{\text{interaction}} < 0.001$ ). When considering late follow-up cases

**TABLE 3** Association between LIBRA score and dementia incidence.

LIBRA score	Model 1, HR (95% CI)	Model 2, HR (95% CI)	Model 3, HR (95% CI)
<b>Across complete follow-up</b>			
Continuous <sup>a</sup>	1.07 (1.05 to 1.09)	1.06 (1.04 to 1.08)	1.05 (1.03 to 1.08)
Lowest tertile	Reference	Reference	Reference
Middle tertile	1.19 (1.03 to 1.40)	1.13 (0.99 to 1.30)	1.08 (0.90 to 1.30)
Highest tertile	1.44 (1.26 to 1.65)	1.33 (1.18 to 1.50)	1.28 (1.10 to 1.49)
<b>Early follow-up (≤ 5 years after baseline)</b>			
Continuous <sup>a</sup>	1.07 (1.04 to 1.10)	1.06 (1.03 to 1.09)	1.06 (1.02 to 1.09)
Lowest tertile	Reference	Reference	Reference
Middle tertile	1.16 (0.98 to 1.38)	1.08 (0.93 to 1.26)	1.04 (0.87 to 1.24)
Highest tertile	1.41 (1.19 to 1.68)	1.30 (1.13 to 1.51)	1.30 (1.08 to 1.56)
<b>Late follow-up (&gt; 5 years after baseline)</b>			
Continuous <sup>a</sup>	1.07 (1.04 to 1.10)	1.06 (1.03 to 1.09)	1.07 (1.03 to 1.10)
Lowest tertile	Reference	Reference	Reference
Middle tertile	1.23 (1.03 to 1.47)	1.20 (1.00 to 1.43)	1.15 (0.92 to 1.44)
Highest tertile	1.47 (1.22 to 1.77)	1.40 (1.16 to 1.69)	1.43 (1.14 to 1.81)

Note: Model 1 controlled for age (time scale). Model 2 (main model): Model 1 + sex and years of formal education. Model 3: Model 2 + socioeconomic position. Abbreviations: CI, confidence interval; HR, hazard ratio; LIBRA, Lifestyle for BRAin Health.

<sup>a</sup>per one-point increase.



**FIGURE 4** Hazard ratio for incident dementia per one-point increase in LIBRA score per sociodemographic group. Model 2 (main model), controlled for age (time scale), sex, and years of formal education. CI, confidence interval; HR, hazard ratio; LIBRA, Lifestyle for BRAin Health; SEP, socioeconomic position.

(occurring after at least 5 years), baseline age did not alter the association between LIBRA and dementia incidence (Cochran's Q test, Model 2 younger: 1.04, 95% CI = 1.00 to 1.08, vs older: 1.06, 95% CI = 1.02 to 1.10,  $p_{\text{interaction}} = 0.545$ ). Meta-regression analysis confirmed these

results: median baseline age was a significant moderator in the early follow-up period but not in the late follow-up period. Lastly, across the entire follow-up period, the association between LIBRA and incident dementia was found to be stronger in Asian cohorts (1.10, 95% CI = 1.07 to 1.14) compared to European cohorts (1.04, 95% CI = 1.02 to 1.07,  $p_{\text{interaction}} = 0.069$ ). However, when examining this difference for early and late follow-up separately, there was no significant effect modification by geographical region (early follow-up Asian cohorts: 1.09, 95% CI = 1.06 to 1.13), vs early follow-up European cohorts: 1.05, 95% CI = 1.00 to 1.10,  $p_{\text{interaction}} = 0.599$ ; late follow-up Asian cohorts: 1.14, 95% CI = 0.98 to 1.31, vs late follow-up European cohorts: 1.06, 95% CI = 1.01 to 1.10,  $p_{\text{interaction}} = 0.610$ ). These findings were confirmed in the meta-regression analysis. Full results on the stratified meta-analysis can be found in [Material S5](#) and detailed results of the meta-regression can be found in [Material S6](#). A sensitivity analysis omitting the H70 study cohort because of non-proportional hazards was also run. The results were similar and can be seen in [Material S7](#).

## 4 | DISCUSSION

In this individual participant data meta-analysis, modifiable dementia risk profiles from diverse ethno-regional groups were examined in 21 prospective cohort studies from 17 countries. An unfavorable modifiable risk profile was associated with an increased risk for dementia, and this association was stronger with younger baseline ages (≤75 years), specifically for dementia cases occurring in the first 5 years of follow-up. Across the entire follow-up time, the association between LIBRA index and incident dementia appeared stronger in Asian compared to European cohorts. However, this interaction

disappeared when considering early and late follow-up cases separately. Importantly, no interactions between modifiable risk profiles and other sociodemographic variables (ie, sex, years of formal education, SEP) were observed.

First, this study examined the association between modifiable risk factors and dementia incidence at a global scale. So far, the link between modifiable risk factors and dementia risk has been predominantly based on studies from high income Western countries, while estimates from low- and middle-income countries (LMICs) were lacking. Yet, the largest increase in dementia prevalence is projected for LMICs.<sup>4,57</sup> The current study included cohorts from six LMICs (Bambui from Brazil, CLAS, and SAS from China, LRGS TUA from Malaysia, EPIDEMCA from the Republic of Congo, and ISA from Nigeria; see Table 1 for expansions of cohort name abbreviations). Our findings suggest that modifiable risk factors are relevant for dementia risk reduction in different parts of the world and might have important implications for global efforts to reduce dementia risk.<sup>1,58</sup>

Across the entire follow-up period, the association between the LIBRA score and incident dementia was stronger in Asian cohorts compared to European cohorts. Previous research suggests that Asian individuals show greater susceptibility to type 2 diabetes, cardiovascular disease, stroke, and associated mortality than White individuals, even when exposure to modifiable risk factors for these outcomes (eg, elevated body mass index or serum triglycerides) is similar.<sup>55-57</sup> However, this stronger association between LIBRA and dementia risk within the Asian cohorts was not observed when considering early and late follow-up cases separately. This may be because of insufficient power to detect in an interaction, especially within late follow-up. In early follow-up, however, sample size of Asian cohorts was still large. Upon further investigation, a suppressor effect between follow-up time and geographical region was noticed, in which controlling for follow-up resulted in a larger estimated effect of geographical region, as well as a significant effect of follow-up time (with longer follow-up time being associated with a larger HR). Without controlling for region, no significant effect of follow-up time was noticed as Asian cohorts tended to have a shorter follow-up time compared to European and American cohorts. We therefore contemplate that the unobserved interaction between LIBRA and geographical region in early follow-up is mostly due to the fact that region and follow-up time suppress each other when they are not both included in the model. When splitting survival time, the effect of follow-up time is modelled less well. Other work looking at ethnic and/or regional differences in susceptibility is limited. One 10/66 Dementia Research Group population-based study compared multiple dementia risk prediction models (including modifiable risk factors) for their predictive validity in LMICs (China and several Latin American countries).<sup>59</sup> All assessed prediction models were developed based on Western, and predominantly White, populations. They found that ANU-ADRI and the Brief Dementia Screening Indicator (BDSI<sup>60</sup>) replicated well in the studied LMICs, but the Cardiovascular Risk Factors, Aging and Dementia (CAIDE<sup>61</sup>) risk score did not. It remains unclear whether there are ethno-regional differences in susceptibility to modifiable risk factors for dementia. More research is needed.

No interactions were observed between the LIBRA score and sex, years of formal education, or SEP. A healthy lifestyle or favorable risk profile thus appears to be associated with a lower risk for dementia to a similar degree in all assessed groups. It is important to note that individuals with more years of formal education or a higher SEP tended to have a more favorable risk factor profile. The lack of effect modification by education or SEP is in line with a limited number of earlier findings, originating from Western countries.<sup>9-11</sup> A previous COSMIC study examining the potential interaction between sex and specific modifiable risk factors also concluded that there was generally no interaction,<sup>12</sup> but other studies have shown varying results.<sup>13-15</sup>

Age interacted with the LIBRA score, which is in line with earlier findings, demonstrating that LIBRA is (more) predictive of incident dementia in individuals in mid-to-early-late life compared to individuals in late-late life. For example, the Cambridge City over-75s cohort study found no association between the LIBRA score—nor its individual risk factors—and dementia risk in individuals over 85 years old,<sup>7</sup> whereas an association between LIBRA and incident dementia is consistently reported in younger populations.<sup>10,17,46</sup> Similar results were observed in another study using data from the European population-based DESCRIPA study.<sup>44</sup> From a life course perspective, one may indeed expect more benefit from adhering to a healthy lifestyle at a younger age, before the pathological process of decades of exposure to risk factors has caused extensive damage.<sup>62</sup> Interestingly, this interaction was specifically observed for early dementia cases that occurred within the first 5 years after baseline. In other words, when a dementia diagnosis occurs within 5 years after the risk profile assessment (when the likelihood for reverse causality is much larger), the risk profile is more strongly associated with dementia risk in the younger ( $\leq 75$  years) individuals. Potentially, the older the age at baseline, the more time might be needed for effects of the risk factor profile on dementia risk to become noticeable, as exposure to risk factors before that time has played a larger role. However, this result may also be related to a larger proportion of the sample being Asian in early follow-up compared to late follow-up. Asian cohorts tended to be younger and were associated with a larger HR compared to European cohorts. Overall, this demonstrates again that it is important to consider the timing of these diagnoses.

The current results hint at universal prevention initiatives. However, this study only considered a small part of the many steps there are between the establishment of a modifiable risk factor (or clustering of multiple risk and protective factors) and the actual evidence-based implementation of effective strategies aimed at altering the exposure to them (for example, this is also dependent on risk factor prevalence or cost-effectiveness).

#### 4.1 | Strengths and limitations

Strengths of this study include its overall sample size and sufficiently high number of incident dementia cases for finding associations. Due to the relatively large amount of individual participant data, we were able to use more refined and elaborate analysis methods. Nonetheless, it is

important to consider that during the process of data harmonization, information can get lost which may result in bias. The global context of this study is uncommon and leads to good external validity. However, data from South America, Africa, Oceania, and certain Asian regions (especially the Middle East and Central Asia) were still limited. Therefore, our results on potential effect modification by geographical region need to be replicated. Furthermore, potential differences based on geographical location, as well as race and ethnicity, should ideally be examined. Due to the nature of the data here, with a very high level of overlap between these two variables, doing so was not reasonable. Instead, we had to focus on one variable and geographical location was chosen because it was readily available for all cohorts and meant a larger sample size. Race and ethnicity were not adequately assessed in several of the cohorts that we aimed to include. Further, we were not able to control for apolipoprotein E (APOE) ε4 allele carriership and information on treatments (eg, for managing dyslipidemia or hypertension) was not always available. Another limitation lies in the fact that we looked at the presence of risk factors at just one timepoint during the lives of these individuals. Also, the studied outcome was incident dementia diagnosis, which is not equivalent to the onset of underlying disease, and may also depend on the healthcare system, testing procedures, and so on. Additionally, for some cohorts many individuals were excluded as they did not meet the preset inclusion criteria. They often differed from the included individuals (see [Material S3](#)). In general, younger, more educated, and healthier individuals were included. Included individuals were more likely to have dyslipidemia compared to excluded individuals. Loss to follow-up or dropout due to worse health (ie, multiple comorbidities) is a recurrent observation in longitudinal studies but cannot be remediated easily. Indeed, most people were excluded because they only had cross-sectional data. This could have resulted in an underestimation of observed associations.

Taken together, these results suggest that a “brain-healthy” lifestyle is associated with a lower risk for dementia years later, regardless of geographical location or sociodemographic characteristics. However, exposure to these modifiable risk and protective factors varied greatly across the ethno-regionally diverse cohorts. Further research towards risk stratification and personalization is needed and should focus on a life course approach, examining the association between a brain-healthy lifestyle and dementia risk at different timepoints during the entire life.<sup>63</sup>

## AFFILIATIONS

<sup>1</sup>Alzheimer Centrum Limburg, Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, The Netherlands

<sup>2</sup>Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia

<sup>3</sup>René Rachou Institute, Fiocruz Minas, Belo Horizonte, Minas Gerais, Brazil

<sup>4</sup>Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil

<sup>5</sup>Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

<sup>6</sup>Department of Psychiatry & Affective Disorders Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

<sup>7</sup>Alzheimer's Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China

<sup>8</sup>Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA

<sup>9</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA

<sup>10</sup>Department of Psychiatry and Behavioral Medicine, Albert Einstein College of Medicine, Bronx, New York, USA

<sup>11</sup>Inserm U1094, IRD UMR270, University Limoges, CHU Limoges, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France

<sup>12</sup>Department of Neurology, Amitié Hospital, Bangui, Central African Republic

<sup>13</sup>Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, Montpellier, France

<sup>14</sup>Institut du Cerveau Trocadéro, Paris, France

<sup>15</sup>Department of Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy, at the University of Gothenburg, Gothenburg, Sweden

<sup>16</sup>Centre for Ageing and Health (AGECAP), University of Gothenburg, Gothenburg, Sweden

<sup>17</sup>Region Västra Götaland, Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden

<sup>18</sup>Department of Clinical Genetics, Section Genomics of Neurodegenerative Diseases and Aging, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

<sup>19</sup>Department of Neurobiology, Aging Research Center, Care Sciences and Society, Karolinska Institute and Stockholm University, Stockholm, Sweden

<sup>20</sup>1st Department of Neurology, Aiginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

<sup>21</sup>Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA

<sup>22</sup>Department of Nutrition and Dietetics, Harokopio University, Athens, Greece

<sup>23</sup>School of Medicine, University of Thessaly, Larissa, Greece

<sup>24</sup>Golgi Cenci Foundation, Milan, Italy

<sup>25</sup>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

<sup>26</sup>Department of Psychiatry, WHO Collaborating Centre for Research and Training in Mental Health, Neuroscience and Substance Abuse, University of Ibadan, Ibadan, Nigeria

<sup>27</sup>Department of Psychiatry, College of Medicine University of Ibadan, Ibadan, Nigeria

<sup>28</sup>Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

<sup>29</sup>Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea

<sup>30</sup>Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Republic of Korea

<sup>31</sup>Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

<sup>32</sup>Department of Internal Medicine, section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands

<sup>33</sup>Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands

<sup>34</sup>Institute of Social Medicine, Occupational Health and Public Health, Medical Faculty, University of Leipzig, Leipzig, Germany

<sup>35</sup>Health and Ageing Research Team (HART), School of Psychology, Massey University, Palmerston North, Aotearoa New Zealand

- <sup>36</sup>Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- <sup>37</sup>Center for Healthy Ageing & Wellness (H-CARE), Faculty of Health Sciences, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia
- <sup>38</sup>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- <sup>39</sup>Departments of Neurology, and Epidemiology, University of Pittsburgh School of Medicine and School of Public Health, Pittsburgh, Pennsylvania, USA
- <sup>40</sup>Department of Graduate Studies in Health and Rehabilitation Sciences, Bitonte College of Health and Human Services, Youngstown State University, Youngstown, Ohio, USA
- <sup>41</sup>Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, California, USA
- <sup>42</sup>Columbia Aging Center and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA
- <sup>43</sup>Institute of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- <sup>44</sup>Center for Liberal Arts, Fukuoka Institute of Technology, Higashi-ku, Fukuoka, Japan
- <sup>45</sup>Department of Physical Education, Sports and Health Research Center, Tongji University, Shanghai, China
- <sup>46</sup>Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- <sup>47</sup>Department of Psychological Medicine, Gerontology Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- <sup>48</sup>Department of Developmental Disability Neuropsychiatry, Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia
- <sup>49</sup>Department of Medicine and Psychiatry, Universidad de Zaragoza, Zaragoza, Spain
- <sup>50</sup>Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
- <sup>51</sup>CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain
- <sup>52</sup>Department of Public Health, Universidad de Zaragoza, Zaragoza, Spain
- <sup>53</sup>Neuropsychiatric Institute, The Prince of Wales Hospital, Sydney, New South Wales, Australia

## ACKNOWLEDGMENTS

The head of COSMIC is Perminder S. Sachdev, and the study coordinator is Darren M. Lipnicki. The research scientific committee leads the scientific agenda of COSMIC and provides ongoing support and governance; it is comprised of member study leaders. The COSMIC research scientific committee and additional principal investigators are listed at <https://cheba.unsw.edu.au/consortia/cosmic/scientific-committee>. Further, the InveCe.Ab study is deeply indebted to "Associazione Alzheimer Milano" for partially funding the study and for having supervised the correctness of the execution of the InveCe.Ab study. The ZARADEMP study acknowledges the contribution of the lay interviewers, senior medical students, and members of the ZARADEMP Workgroup who participated in the study. The Bambui study acknowledges the Brazilian National Research Council (CNPq). The CLAS study thanks all the investigators, participants, caregivers, and families who participated in this study. LRGS Tua acknowledges the Ministry of Education Malaysia. The EPIDEMCA study acknowledges the Universities of Bangui (CAR) and Marien Ngouabi in Brazzaville (Congo), Institut Pasteur in Bangui and Laboratoire National de

Santé Publique in Brazzaville, Health ministries of the Central African Republic and the Republic of Congo, for their moral support and all the participants to this survey, the investigators, and staffs of Bangui and Brazzaville hospitals for their assistance. SGS acknowledges Drs. Shuzo Kumagai, Yu Nofuji, Takanori Honda, and the other contributors to the study. COSMIC received funding from the National Institute on Aging of the National Institutes of Health (Award number: RF1AG057531). The Maastricht Aging Study (MAAS) is supported by the Maastricht University Medical Center+ and was supported by the Dutch government through a grant from the Netherlands Programme for Research on Aging (NESTOR). KD was funded by the Dutch Organization for Health Research and Development (ZonMw) (grant number: 733050511). Funding for the Ibadan Study of Ageing was provided by Wellcome Trust. The InveCe.Ab study was funded by Associazione Alzheimer Milano and Fondazione CARIPLO, FrailBioTrack Project (grant 2017-0557). The ZARADEMP study was supported by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, 12/02254, 16/00896, PI/19/01874, G03/128) and from the Fondo Europeo de Desarrollo Regional (FEDER) of the European Union "Una manera de hacer Europa" (Project number PI16/00896) and Gobierno de Aragón (grant B15\_17R and B15\_23R). Funding for the HELIAD study consists of the following: IIRG-09-133014; Alzheimer's Association, Grant/Award Number: 189 10276/8/9/2011; National Strategic Reference Framework (NSFR)—EU Program Excellence Grant (ARISTEIA); European Social Fund and Greek National Resources; Ministry for Health and Social Solidarity (Greece). CLAS was funded by the China Ministry of Science and Technology (grant number: 2009BAI77B03), the Clinical Research Center, Shanghai Mental Health Center (grant number: CRC2017ZD02), and Shanghai Brain Health Foundation. The SLAS work was supported by research grants in Singapore from the Agency for Science Technology and Research (A\*STAR) Biomedical Research Council (grant number BMRC/08/1/21/19/567) and the National Medical Research Council (grant numbers NMRC/1108/2007, NMRC/CIRG/1409/2014). The EPIDEMCA study was funded by the French National Research Agency (ANR) (grant: ANR-09-MNPS-009-01); the AXA Research Fund (grant: 2012–Project Public Health Institute [Inserm]–PREUX Pierre-Marie), and the Limoges University Hospital through its Appel à Projet des Equipes Émergentes et Labellisées scheme (APREL). Einstein Aging Study (EAS) funding sources consist of NIH/NIA AG03949: the Leonard and Sylvia Marx Foundation; and the Czap Foundation. MYHAT was supported by NIH/NIA (grant: R37AG02365). The Longitudinal Study on Neuroprotective Model for Healthy Longevity (LRGS-TUA) cohort was supported by the Long-term Research Grant Scheme (LGRS) provided by the Ministry of Higher Education, Malaysia (LRGS/1/2019/UM-UKM/1/4, LRGS/BU/2012/UKM-UKM/K/01) and Universiti Kebangsaan Malaysia Grand Challenge Grant Projects (DCP-2017-002/1, DCP-2017-002/2). LEILA75+ was funded by The Interdisciplinary Centre for Clinical Research at the University of Leipzig (Interdisziplinäres Zentrum für Klinische Forschung/IZKF) (grant: 01KS9504). The SGS study was funded by JSPS KAKENHI



(grant number: JP17K09146 and 20H04030) for KN. The H70 study was supported by AgeCap-Center for Aging and Health, Riksbankens Jubileumsfond, FORTE, and the Swedish Brain Power. The H70 study data collection was supported by The Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, Epilife, Swedish Brain Power, The Alzheimer's Association Zenith Award, The Alzheimer's Association Stephanie B Overstreet Scholars, The Bank of Sweden Tercentenary Foundation, Stiftelsen Söderström-Königskas Sjukhemmet, Stiftelsen för Gamla Tjänarinnor, Handlanden Hjalmar Svenssons Forskningsfond, and Stiftelsen Professor Bror Gadelius' Minnesfond. JN was funded by Alzheimersfonden (AF-967865), the ALF-agreement (72660), and Stiftelsen Hjalmar Svenssons forskningsfond (HJSV2022059, HJSV2023023). Funding parties had no role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

### CONFLICT OF INTEREST STATEMENT

AL has received financial support to attend scientific meetings from Janssen. PG has received financial support to attend scientific meetings from Lundbeck, Esteve, Nutrición Médica, Angelini, and Neuraxpharm. DD reports grants from Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJ LAB, National Natural Science Foundation of China (82173599, 81773513), Scientific Research Plan Project of Shanghai Science and Technology Committee (17411950701, 17411950106), and National Project of Chronic Disease (2016YFC1306402); all payments were made to the institution. QZ reports grants from the National Chronic Disease Project (2016YFC1306402), Shanghai Science and Technology Municipality (17411950106, 2018SHZDZX03, 17411950701), National Natural Science Foundation of China (82071200, 81773513), Shanghai Hospital Development Center (SHDC2020CR4007), and MOE Frontiers Center for Brain Science (J1H2642001/028); all payments were made to the institution. NS declares personal fees from NIH, grants from Novo Nordisk (not related to current manuscript). All other authors do not have any conflicts of interest to declare. Author disclosures are available in the [supporting information](#).

### CONSENT STATEMENT

All participants provided informed consent.

### DATA AVAILABILITY STATEMENT

Data were provided by the contributing studies on the understanding and proviso that the relevant study leaders be contacted for further use of their data and additional formal data sharing agreements be made. Researchers can apply to use COSMIC data by completing a COSMIC Research Proposal Form available from <https://cheba.unsw.edu.au/consortia/cosmic/research-proposals>.

### ORCID

Stephanie Van Asbroeck  <https://orcid.org/0000-0002-2077-0366>

### REFERENCES

1. World Health Organisation (WHO). Global status report on the public health response to dementia. 2021.
2. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. *Nat Rev Neurol*. 2018;14(11):653-666. doi:10.1038/s41582-018-0070-3
3. Rolandi E, Zaccaria D, Vaccaro R, et al. Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study. *Alzheimers Res Ther*. 2020;12(1):94. doi:10.1186/s13195-020-00661-y
4. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
5. World Health Organization (WHO). Risk reduction of cognitive decline and dementia: WHO guidelines. 2019.
6. Altomare D, Molinuevo JL, Ritchie C, et al. Brain health services: organization, structure, and challenges for implementation. A user manual for brain health services-part 1 of 6. *Alzheimers Res Ther*. 2021;13(1):168. doi:10.1186/s13195-021-00827-2
7. Deckers K, Kohler S, van Boxel M, Verhey F, Brayne C, Fleming J. Lack of associations between modifiable risk factors and dementia in the very old: findings from the Cambridge City over-75s cohort study. *Aging Ment Health*. 2018;22(10):1272-1278. doi:10.1080/13607863.2017.1280767
8. Deckers K, van Boxel MP, Schiepers OJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry*. 2015;30(3):234-246. doi:10.1002/gps.4245
9. Hu EA, Wu A, Dearborn JL, et al. Adherence to dietary patterns and risk of incident dementia: findings from the atherosclerosis risk in communities study. *J Alzheimers Dis*. 2020;78(2):827-835. doi:10.3233/JAD-200392
10. Deckers K, Nooyens A, van Boxel M, Verhey F, Verschuren M, Kohler S. Gender and educational differences in the association between lifestyle and cognitive decline over 10 years: the Doetinchem cohort study. *J Alzheimers Dis*. 2019;70(s1):S31-S41. doi:10.3233/JAD-180492
11. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. *Alzheimers Dement*. 2018;14(3):263-270. doi:10.1016/j.jalz.2017.09.006
12. Gong J, Harris K, Lipnicki DM, et al. Sex differences in dementia risk and risk factors: individual-participant data analysis using 21 cohorts across six continents from the COSMIC consortium. *Alzheimers Dement*. 2023;19(8):3365-3378. doi:10.1002/alz.12962
13. Mewton L, Visontay R, Hoy N, et al. The relationship between alcohol use and dementia in adults aged more than 60 years: a combined analysis of prospective, individual-participant data from 15 international studies. *Addiction*. 2023;118(3):412-424. doi:10.1111/add.16035
14. Makkar SR, Lipnicki DM, Crawford JD, et al. Education and the moderating roles of age, sex, ethnicity and apolipoprotein epsilon 4 on the risk of cognitive impairment. *Arch Gerontol Geriatr*. 2020;91:104112. doi:10.1016/j.archger.2020.104112
15. Samtani S, Mahalingam G, Lam BCP, et al. Associations between social connections and cognition: a global collaborative individual participant data meta-analysis. *Lancet Healthy Longev*. 2022;3(11):e740-e753. doi:10.1016/S2666-7568(22)00199-4
16. Lipnicki DM, Makkar SR, Crawford JD, et al. Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: a COSMIC collaboration cohort study. *PLoS Med*. 2019;16(7):e1002853. doi:10.1371/journal.pmed.1002853



17. Schiepers OJG, Kohler S, Deckers K, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. *Int J Geriatr Psychiatry*. 2018;33(1):167-175. doi:10.1002/gps.4700
18. Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. *Prev Sci*. 2013;14(4):411-421. doi:10.1007/s11211-012-0313-2
19. Anstey KJ, Zheng L, Peters R, et al. Dementia risk scores and their role in the implementation of risk reduction guidelines. *Front Neurol*. 2021;12:765454. doi:10.3389/fneur.2021.765454
20. Huque MH, Kootar S, Eramudugolla R, et al. CogDrisk, ANU-ADRI, CAIDE, and LIBRA risk scores for estimating dementia risk. *JAMA Netw Open*. 2023;6(8):e2331460. doi:10.1001/jamanetworkopen.2023.31460
21. Sachdev PS, Lipnicki DM, Kochan NA, et al. COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. *BMC Neurol*. 2013;13:165. doi:10.1186/1471-2377-13-165
22. Lima-Costa MF, Firmo JO, Uchoa E. Cohort profile: the Bambui (Brazil) cohort study of ageing. *Int J Epidemiol*. 2011;40(4):862-867. doi:10.1093/ije/dyq143
23. Xiao S, Lewis M, Mellor D, et al. The China longitudinal ageing study: overview of the demographic, psychosocial and cognitive data of the Shanghai sample. *J Ment Health*. 2016;25(2):131-136. doi:10.3109/09638237.2015.1124385
24. Katz MJ, Lipton RB, Hall CB, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. *Alzheimer Dis Assoc Disord*. 2012;26(4):335-343. doi:10.1097/WAD.0b013e31823dbcf
25. Guerchet M, Mbelesso P, Ndamba-Bandzouzi B, et al. Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre population-based study in rural and urban areas of the Central African Republic and the Republic of Congo. *Springerplus*. 2014;3(1):338. doi:10.1186/2193-1801-3-338
26. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ*. 2010;341:c3885. doi:10.1136/bmj.c3885
27. Rydberg Sterner T, Ahlner F, Blennow K, et al. The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. *Eur J Epidemiol*. 2019;34(2):191-209. doi:10.1007/s10654-018-0459-8
28. Dardiotis E, Kosmidis MH, Yannakoulia M, Hadjigeorgiou GM, Scarmeas N. The Hellenic Longitudinal Investigation of Aging and Diet (HELIAD): rationale, study design, and cohort description. *Neuroepidemiology*. 2014;43(1):9-14. doi:10.1159/000362723
29. Guaita A, Colombo M, Vaccaro R, et al. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. *BMC Geriatr*. 2013;13:98. doi:10.1186/1471-2318-13-98
30. Gureje O, Ogunniyi A, Kola L, Abiona T. Incidence of and risk factors for dementia in the Ibadan study of aging. *J Am Geriatr Soc*. 2011;59(5):869-874. doi:10.1111/j.1532-5415.2011.03374.x
31. Han JW, Kim TH, Kwak KP, et al. Overview of the Korean longitudinal study on cognitive aging and dementia. *Psychiatry Investig*. 2018;15(8):767-774. doi:10.30773/pi.2018.06.02
32. der Wiel AB, van Exel E, de Craen AJ, et al. A high response is not essential to prevent selection bias: results from the Leiden 85-plus study. *J Clin Epidemiol*. 2002;55(11):1119-1125. doi:10.1016/s0895-4356(02)00505-x
33. Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Prevalence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+) Part 1. *Br J Psychiatry*. 2001;179:250-254. doi:10.1192/bjp.179.3.250
34. Shahar S, Omar A, Vanoh D, et al. Approaches in methodology for population-based longitudinal study on neuroprotective model for healthy longevity (TUA) among Malaysian older adults. *Aging Clin Exp Res*. 2016;28(6):1089-1104. doi:10.1007/s40520-015-0511-4
35. van Boxtel MP, Buntinx F, Houx PJ, Metsemakers JF, Knottnerus A, Jolles J. The relation between morbidity and cognitive performance in a normal aging population. *J Gerontol A Biol Sci Med Sci*. 1998;53(2):M147-M154. doi:10.1093/gerona/53a.2.m147
36. Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. *Neurology*. 2000;54(5):1109-1116. doi:10.1212/wnl.54.5.1109
37. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. *J Am Geriatr Soc*. 2003;51(2):169-177. doi:10.1046/j.1532-5415.2003.51054.x
38. Ding D, Zhao Q, Guo Q, et al. The Shanghai Aging Study: study design, baseline characteristics, and prevalence of dementia. *Neuroepidemiology*. 2014;43(2):114-122. doi:10.1159/000366163
39. Narazaki K, Nofuji Y, Honda T, Matsuo E, Yonemoto K, Kumagai S. Normative data for the montreal cognitive assessment in a Japanese community-dwelling older population. *Neuroepidemiology*. 2013;40(1):23-29. doi:10.1159/000339753
40. Feng L, Chong MS, Lim WS, et al. Metabolic syndrome and amnesic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings. *J Alzheimers Dis*. 2013;34(3):649-657. doi:10.3233/JAD-121885
41. Sachdev PS, Brodaty H, Reppermund S, et al. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological nondemented cohort of Australians aged 70-90 years. *Int Psychogeriatr*. 2010;22(8):1248-1264. doi:10.1017/S1041610210001067
42. Lobo A, Saz P, Marcos G, et al. The ZARADEMP Project on the incidence, prevalence and risk factors of dementia (and depression) in the elderly community: II. Methods and first results. *Eur J Psychiat*. 2005;19(1):40-54.
43. Lima-Costa MF, Rodrigues LC, Barreto ML, et al. Genomic ancestry and ethnorracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative). *Sci Rep*. 2015;5:9812. doi:10.1038/srep09812
44. Vos SJB, van Boxtel MPJ, Schiepers OJG, et al. Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA Index. *J Alzheimers Dis*. 2017;58(2):537-547. doi:10.3233/JAD-161208
45. Deckers K, Barbera M, Kohler S, et al. Long-term dementia risk prediction by the LIBRA score: a 30-year follow-up of the CAIDE study. *Int J Geriatr Psychiatry*. 2020;35(2):195-203. doi:10.1002/gps.5235
46. Deckers K, Cadar D, van Boxtel MPJ, Verhey FRJ, Steptoe A, Kohler S. Modifiable risk factors explain socioeconomic inequalities in dementia risk: evidence from a population-based prospective cohort study. *J Alzheimers Dis*. 2019;71(2):549-557. doi:10.3233/JAD-190541
47. Pons A, LaMonica HM, Mowszowski L, Kohler S, Deckers K, Naismith SL. Utility of the LIBRA index in relation to cognitive functioning in a clinical health seeking sample. *J Alzheimers Dis*. 2018;62(1):373-384. doi:10.3233/JAD-170731
48. Heger IS, Deckers K, Schram MT, et al. Associations of the lifestyle for brain health index with structural brain changes and cognition: results from the Maastricht study. *Neurology*. 2021;97(13):e1300-e1312. doi:10.1212/WNL.00000000000012572
49. American Psychiatric Association. *Work Group to Revise DSM-III. Diagnostic and statistical manual of mental disorders: DSM-III-R*. 3rd ed. American Psychiatric Association; 1987.

50. American Psychiatric Association. *Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders IV*. 4th ed. Published by the American Psychiatric Association; 1994.
51. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412-2414. doi:10.1212/wnl.43.11.2412-a
52. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6
53. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol*. 2007;165(6):710-718. doi:10.1093/aje/kwk052
54. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1):239-241.
55. Chapter 9: analysing data and undertaking meta-analyses. In Higgins JPT, Green S, eds. *Chapter 9: analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.10 [updated March 2011]*. The Cochrane Collaboration; 2011.
56. The World Bank. GDP per capita (current US\$). Internet. Accessed 13/09/2022. <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>
57. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health*. 2022;7(2):e105-e125. doi:10.1016/S2468-2667(21)00249-8
58. Gauthier S, Webster C, Servaes S, Morais JA, Rosa-Neto P, World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. 2022.
59. Stephan BCM, Pakpahan E, Siervo M, et al. Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models. *Lancet Glob Health*. 2020;8(4):e524-e535. doi:10.1016/S2214-109X(20)30062-0
60. Barnes DE, Beiser AS, Lee A, et al. Development and validation of a brief dementia screening indicator for primary care. *Alzheimers Dement*. 2014;10(6):656-665. e1. doi:10.1016/j.jalz.2013.11.006
61. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol*. 2006;5(9):735-741. doi:10.1016/S1474-4422(06)70537-3
62. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA*. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668
63. Litkouhi PN, Numbers K, Valenzuela M, et al. Critical periods for cognitive reserve building activities for late life global cognition and cognitive decline: the Sydney memory and aging cohort study. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*. 2023;1-17. doi:10.1080/13825585.2023.2181941

### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Van Asbroeck S, Köhler S, van Boxtel MPJ, et al. Lifestyle and incident dementia: A COSMIC individual participant data meta-analysis. *Alzheimer's Dement*. 2024;1-15. <https://doi.org/10.1002/alz.13846>